Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Inhibikase Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -131.71%, provide a clear picture of how effectively IKT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IKT competes directly with industry leaders such as CLLS and CHRS. With a market capitalization of $234.05M, it holds a significant position in the sector. When comparing efficiency, IKT's gross margin of N/A stands against CLLS's 32.13% and CHRS's 67.84%. Such benchmarking helps identify whether Inhibikase Therapeutics Inc is trading at a premium or discount relative to its financial performance.
